 <h1>Deferoxamine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to deferoxamine: injection powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, deferoxamine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking deferoxamine:</p><p>
<i>More common</i>
</p><ul>
<li>Bluish fingernails, lips, or skin</li>
<li>blurred vision or other problems with vision</li>
<li>convulsions (seizures)</li>
<li>difficulty with breathing or fast breathing</li>
<li>fast heartbeat</li>
<li>hearing problems</li>
<li>redness or flushing of the skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Diarrhea</li>
<li>difficult urination</li>
<li>fever</li>
<li>leg cramps</li>
<li>nausea</li>
<li>stomach and muscle cramps</li>
<li>stomach discomfort</li>
<li>unusual bleeding or bruising</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>coma</li>
<li>confusion</li>
<li>cough</li>
<li>decreased urine output</li>
<li>depression</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>headache</li>
<li>hives</li>
<li>hostility</li>
<li>irritability</li>
<li>itching</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>lethargy</li>
<li>muscle twitching</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid weight gain</li>
<li>shortness of breath</li>
<li>skin rash</li>
<li>stupor</li>
<li>swelling of the face, ankles, or hands</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
<li>wheezing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of deferoxamine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
</ul><p>
<!-- end injection powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to deferoxamine: injectable powder for injection</i></p><h3>General</h3><p>The most common adverse events were injection site reactions (pain, swelling, infiltration, erythema, pruritus, eschar/crust), and arthralgia/myalgia.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Pain, swelling, infiltration, erythema, pruritus, eschar/crust at the injection site</p>
<p><b>Uncommon</b> (0.1% to 1%): Vesicles, local edema, local burning<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia/myalgia</p>
<p><b>Common</b> (1% to 10%): Growth retardation, bone disorder (e.g.  metaphyseal dysplasia)</p>
<p><b>Frequency not reported</b>: Muscle spasms, leg cramps, transient bone pain, hyperparathyroid bone disease<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): Vomiting, abdominal pain</p>
<p><b>Very rare</b> (less than 0.01%): Diarrhea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Urticaria</p>
<p><b>Very rare</b> (less than 0.01%): Rash generalized, dermatitis medicamentosa<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Very rare</b> (less than 0.01%): Neurological disturbances, dizziness, precipitation/exacerbation of aluminum-related dialysis encephalopathy (e.g.  grand mal seizures, hallucinations, paranoid delusions, dialysis dementia), neuropathy peripheral, paresthesia</p>
<p><b>Frequency not reported</b>: Convulsion<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pyrexia</p>
<p><b>Rare</b> (less than 0.1%): Deafness neurosensory, tinnitus</p>
<p><b>Frequency not reported</b>: Transient depression of serum calcium, reversible aphasia with visual loss and bradycardia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Asthma</p>
<p><b>Very rare</b> (less than 0.01%): Acute respiratory distress, lung infiltration<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very rare</b> (less than 0.01%): Blood disorders (e.g.  thrombocytopenia, leucopenia, eosinophilia)</p>
<p><b>Frequency not reported</b>: Inhibition of DNA synthesis in T and B lymphocytes<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Hypotension, tachycardia, shock</p>
<p><b>Frequency not reported</b>: Cardiac arrhythmias<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Reddish-brown discoloration of the urine, dysuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (0.01% to 0.1%): Mucormycosis</p>
<p><b>Very rare</b> (less than 0.01%): Gastroenteritis Yersinia, unusual infections (e.g.  Pneumocystis carinii, Yersinia, or Rhizopus)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (less than 0.1%): Loss of vision, scotoma, retinal degeneration, optic neuritis, cataracts, decreased visual acuity, blurred vision, night blindness, visual field defects, chromatopsia, corneal opacities<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very rare</b> (less than 0.01%): Anaphylactic shock, anaphylactoid reaction, angioneurotic edema, allergic skin reactions<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very rare</b> (less than 0.01%): Renal impairment (including a rise in serum creatinine)</p>
<p><b>Frequency not reported</b>: Acute renal failure, renal tubular disorder, blood creatinine increased, aggravation of pyelonephritis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Impaired hepatic function, increased transaminases<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypocalcemia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Aggravation of hyperparathyroidism<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Deferoxamine Mesylate (deferoxamine)." Hospira Inc, Lake Forest, IL. </p><p id="ref_2">2. "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about deferoxamine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: antidotes</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Deferoxamine Injection &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Desferal</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Iron Poisoning, Acute</li>
<li>Iron Poisoning, Chronic</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to deferoxamine: injectable powder for injection</i></p><h3>General</h3><p>The most common adverse events were injection site reactions (pain, swelling, infiltration, erythema, pruritus, eschar/crust), and arthralgia/myalgia.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Pain, swelling, infiltration, erythema, pruritus, eschar/crust at the injection site</p><p><b>Uncommon</b> (0.1% to 1%): Vesicles, local edema, local burning<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia/myalgia</p><p><b>Common</b> (1% to 10%): Growth retardation, bone disorder (e.g.  metaphyseal dysplasia)</p><p><b>Frequency not reported</b>: Muscle spasms, leg cramps, transient bone pain, hyperparathyroid bone disease<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea</p><p><b>Uncommon</b> (0.1% to 1%): Vomiting, abdominal pain</p><p><b>Very rare</b> (less than 0.01%): Diarrhea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Urticaria</p><p><b>Very rare</b> (less than 0.01%): Rash generalized, dermatitis medicamentosa<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p><b>Very rare</b> (less than 0.01%): Neurological disturbances, dizziness, precipitation/exacerbation of aluminum-related dialysis encephalopathy (e.g.  grand mal seizures, hallucinations, paranoid delusions, dialysis dementia), neuropathy peripheral, paresthesia</p><p><b>Frequency not reported</b>: Convulsion<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pyrexia</p><p><b>Rare</b> (less than 0.1%): Deafness neurosensory, tinnitus</p><p><b>Frequency not reported</b>: Transient depression of serum calcium, reversible aphasia with visual loss and bradycardia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Asthma</p><p><b>Very rare</b> (less than 0.01%): Acute respiratory distress, lung infiltration<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very rare</b> (less than 0.01%): Blood disorders (e.g.  thrombocytopenia, leucopenia, eosinophilia)</p><p><b>Frequency not reported</b>: Inhibition of DNA synthesis in T and B lymphocytes<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Hypotension, tachycardia, shock</p><p><b>Frequency not reported</b>: Cardiac arrhythmias<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Reddish-brown discoloration of the urine, dysuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (0.01% to 0.1%): Mucormycosis</p><p><b>Very rare</b> (less than 0.01%): Gastroenteritis Yersinia, unusual infections (e.g.  Pneumocystis carinii, Yersinia, or Rhizopus)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (less than 0.1%): Loss of vision, scotoma, retinal degeneration, optic neuritis, cataracts, decreased visual acuity, blurred vision, night blindness, visual field defects, chromatopsia, corneal opacities<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very rare</b> (less than 0.01%): Anaphylactic shock, anaphylactoid reaction, angioneurotic edema, allergic skin reactions<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very rare</b> (less than 0.01%): Renal impairment (including a rise in serum creatinine)</p><p><b>Frequency not reported</b>: Acute renal failure, renal tubular disorder, blood creatinine increased, aggravation of pyelonephritis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Impaired hepatic function, increased transaminases<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypocalcemia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Aggravation of hyperparathyroidism<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Deferoxamine Mesylate (deferoxamine)." Hospira Inc, Lake Forest, IL. </p><p id="ref_2">2. "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about deferoxamine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: antidotes</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Deferoxamine Injection &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Iron Poisoning, Acute</li>
<li>Iron Poisoning, Chronic</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>